WO2006062424A3 - Use of 3-hydroxy-3-methylbutyrate alone or in combination with alpha-ketoglutarate in the growth and mineralisation of the osteo-skeletal system - Google Patents

Use of 3-hydroxy-3-methylbutyrate alone or in combination with alpha-ketoglutarate in the growth and mineralisation of the osteo-skeletal system Download PDF

Info

Publication number
WO2006062424A3
WO2006062424A3 PCT/PL2005/000071 PL2005000071W WO2006062424A3 WO 2006062424 A3 WO2006062424 A3 WO 2006062424A3 PL 2005000071 W PL2005000071 W PL 2005000071W WO 2006062424 A3 WO2006062424 A3 WO 2006062424A3
Authority
WO
WIPO (PCT)
Prior art keywords
alpha
ketoglutarate
mineralisation
methylbutyrate
osteo
Prior art date
Application number
PCT/PL2005/000071
Other languages
French (fr)
Other versions
WO2006062424A2 (en
Inventor
Tadeusz Studzinski
Marcin Tatara
Piotr Ostaszewski
Stefan Pierzynowski
Original Assignee
Sgp & Sons Ab
Tadeusz Studzinski
Marcin Tatara
Piotr Ostaszewski
Stefan Pierzynowski
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35825427&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2006062424(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sgp & Sons Ab, Tadeusz Studzinski, Marcin Tatara, Piotr Ostaszewski, Stefan Pierzynowski filed Critical Sgp & Sons Ab
Publication of WO2006062424A2 publication Critical patent/WO2006062424A2/en
Publication of WO2006062424A3 publication Critical patent/WO2006062424A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)

Abstract

The invention dissolves the problem of the pharmaceutical preparation affecting the processes of the growth and the mineralisation of the osteo-skeletal system in the physiology and in the osteochondropathy in the matured people and animals. The essence of the invention is that 3-hydroxy-3-methylbutyrate (HMB) and its derivatives such keto-isokaproic acid (KIC) and leucin and isoleucine are used as chemical compound in a dose 0.001-1 g/kg/day, alone or in combination with alpha-ketoglutarate (AKG) or/and glutamines or/and glutamate or/and alpha- ketoglutarate of ornithine or/and dipeptides of glutamine and other amino acids or/and tripeptides of glutamine and other amino acids or/and di- and tripeptides of glutamate with other amino acid, or/and mono- and bivalent metal salts and other alpha-keto of glutarate or/and glutamine or/and glutamate or/and ornithine of alpha-ketoglutarate, in a dose 0.001-1 g/kg/day for producing of the curative preparation, functional and medical food.
PCT/PL2005/000071 2004-11-08 2005-11-07 Use of 3-hydroxy-3-methylbutyrate alone or in combination with alpha-ketoglutarate in the growth and mineralisation of the osteo-skeletal system WO2006062424A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PL371081A PL371081A1 (en) 2004-11-08 2004-11-08 Pharmaceutical compound with the effect on the growth and the mineralization of osseous-skeleton system and on mature years bone and cartilage diseases among humans and animals, and method for its application
PLP.371081 2004-11-08

Publications (2)

Publication Number Publication Date
WO2006062424A2 WO2006062424A2 (en) 2006-06-15
WO2006062424A3 true WO2006062424A3 (en) 2007-02-15

Family

ID=35825427

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/PL2005/000071 WO2006062424A2 (en) 2004-11-08 2005-11-07 Use of 3-hydroxy-3-methylbutyrate alone or in combination with alpha-ketoglutarate in the growth and mineralisation of the osteo-skeletal system

Country Status (2)

Country Link
PL (1) PL371081A1 (en)
WO (1) WO2006062424A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7114458B2 (en) 2015-09-16 2022-08-08 メタボリック・テクノロジーズ，インコーポレーテッド Compositions and methods of use of β-hydroxy-β-methylbutyrate (HMB) to enhance recovery from soft tissue trauma

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050215640A1 (en) 2004-03-26 2005-09-29 Baxter Jeffrey H HMB compositions and uses thereof
RU2454999C2 (en) * 2005-11-15 2012-07-10 Энтресс Аб Drug preparation used for cartilage diseases
NZ568611A (en) 2005-12-19 2011-11-25 Abbott Lab Use of beta-hydroxy-beta-methylbutyrate to modulate the imbalance in type 1 and type 2 cytokine production
DE102007016715A1 (en) * 2007-04-04 2008-10-09 Evonik Degussa Gmbh Nutritional supplement containing alpha-keto acids
AU2011210691A1 (en) 2010-01-29 2012-07-12 Abbott Laboratories Nutritional emulsions comprising calcium HMB
US9693577B2 (en) 2010-01-29 2017-07-04 Abbott Laboratories Method of preparing a nutritional powder comprising spray dried HMB
AU2011210682A1 (en) 2010-01-29 2012-07-05 Abbott Laboratories Aseptically packaged nutritional liquids comprising HMB
TWI526161B (en) 2010-06-10 2016-03-21 亞培公司 Substantially clear nutritional liquids comprising calcium hmb and soluble protein
US9326956B2 (en) 2011-02-17 2016-05-03 Abbott Laboratories Methods for improving brain development and cognitive function using beta-hydroxy-beta methylbutyrate
ES2421187B1 (en) * 2012-02-23 2014-11-26 Abbott Laboratories METHOD FOR IMPROVING BRAIN DEVELOPMENT AND COGNITIVE FUNCTION USING BETA-HIDROXI-BETA-METHYLBUTIRATE

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4883817A (en) * 1987-03-02 1989-11-28 Iowa State University Research Foundation, Inc. Raising chickens for meat production with ketoisocaproate-containing feeds
US5028440A (en) * 1990-01-30 1991-07-02 Iowa State University Research Foundation, Inc. Method of raising meat producing animals to increase lean tissue development
WO1994017678A1 (en) * 1993-02-11 1994-08-18 Iowa State University Research Foundation, Inc. Method of enhancing nutritional value of colostrum and first milk of pregnant mammals
WO2003043626A1 (en) * 2001-11-23 2003-05-30 Essentys Ab Use of glutamate, glutamate derivatives or metabolites, glutamate analogues or mixtures thereof for the manufacture of a composition for the treatment of osteoporosis
WO2003049687A2 (en) * 2001-12-06 2003-06-19 Weller Health, Inc. Medicinal compositions & therapeutic methods
US20040071825A1 (en) * 2002-10-15 2004-04-15 Christopher Lockwood Agglomerated granular protein-rich nutritional supplement
US20040220266A1 (en) * 2002-09-09 2004-11-04 Wiley David B. Composition and method for enhancing the bioavailability of calcium and magnesium in dietary supplements and food additives
WO2005102301A2 (en) * 2004-03-26 2005-11-03 Abbott Laboratories Hydroxymethylbutyrate compositions and uses thereof

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4883817A (en) * 1987-03-02 1989-11-28 Iowa State University Research Foundation, Inc. Raising chickens for meat production with ketoisocaproate-containing feeds
US5028440A (en) * 1990-01-30 1991-07-02 Iowa State University Research Foundation, Inc. Method of raising meat producing animals to increase lean tissue development
WO1994017678A1 (en) * 1993-02-11 1994-08-18 Iowa State University Research Foundation, Inc. Method of enhancing nutritional value of colostrum and first milk of pregnant mammals
WO2003043626A1 (en) * 2001-11-23 2003-05-30 Essentys Ab Use of glutamate, glutamate derivatives or metabolites, glutamate analogues or mixtures thereof for the manufacture of a composition for the treatment of osteoporosis
WO2003049687A2 (en) * 2001-12-06 2003-06-19 Weller Health, Inc. Medicinal compositions & therapeutic methods
US20040220266A1 (en) * 2002-09-09 2004-11-04 Wiley David B. Composition and method for enhancing the bioavailability of calcium and magnesium in dietary supplements and food additives
US20040071825A1 (en) * 2002-10-15 2004-04-15 Christopher Lockwood Agglomerated granular protein-rich nutritional supplement
WO2005102301A2 (en) * 2004-03-26 2005-11-03 Abbott Laboratories Hydroxymethylbutyrate compositions and uses thereof

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7114458B2 (en) 2015-09-16 2022-08-08 メタボリック・テクノロジーズ，インコーポレーテッド Compositions and methods of use of β-hydroxy-β-methylbutyrate (HMB) to enhance recovery from soft tissue trauma

Also Published As

Publication number Publication date
WO2006062424A2 (en) 2006-06-15
PL371081A1 (en) 2006-05-15

Similar Documents

Publication Publication Date Title
WO2006062424A3 (en) Use of 3-hydroxy-3-methylbutyrate alone or in combination with alpha-ketoglutarate in the growth and mineralisation of the osteo-skeletal system
NZ593199A (en) Milnacipran for the long-term treatment of fybromyalgia syndrome
WO2005017094A3 (en) N-acetyl compositions as adjunct therapy for treatment and prevention of cysteine/glutathione deficiency
IL171331A (en) Use of a combination comprising safinamide and levodopa/pdi in the manufacture of a medicament for treating parkinson's disease and compositions and a kit comprising said combination for such a treatment
NZ607189A (en) Materials and methods for improving gastrointestinal function
HK1086186A1 (en) Use of spongosine (2-methoxyadenosein) for preparing pharmaceutical for the treatment of pain
WO2004030611A3 (en) Non-nucleoside reverse transcriptase inhibitors
US7846902B2 (en) Dipeptide-comprising composition for oral administration
TW200740424A (en) Taste masking dosage form
TW200510352A (en) Cycloalkyl substituted amino acid derivatives, processes for their freparation and their use as pharmaceuticals
JP2009515953A5 (en)
JP5985456B2 (en) Oral composition
EP1806983B8 (en) Nutritional and/or pharmaceutical preparation for use in prophylaxis and treatment of disturbances in microelements absorption from the alimentary canal
RU2008123806A (en) MEDICINE USED FOR CARTILAGE DISORDERS
JP2010532348A5 (en)
IL42726A (en) Composition for promotion of protein synthesis and suppression of urea formation in the body
UA102111C2 (en) Single unit oral dose pharmaceutical composition comprising levodopa, carbidopa and entacapone or salts thereof
EP1695969A4 (en) Alpha-amino acid derivatives and use thereof as medicines
ATE451340T1 (en) DEUTERATED CATECHOLAMINE DERIVATIVES AND MEDICINAL PRODUCTS CONTAINING THESE COMPOUNDS
PL1845966T3 (en) Pharmaceutical preparation for use in the treatment or prophylaxis of neoplastic diseases
WO2006129056A3 (en) Process and novel salt
CA3010857A1 (en) Pharmaceutical composition comprising nebivolol with improved dissolution rate
HK1049326A1 (en) Non-hygroscopic salts of active ingredients havingtherapeutical and/or nutritional activities and o rally administrable compositions containing same.
EP2210602B1 (en) Compositions for the treatment of symptoms associated with respiratory inflammations
AU2003294834A1 (en) Anthranilic acid amide derivatives and their pharmaceutical use

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KN KP KR KZ LC LK LR LS LT LU LV LY MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase

Ref document number: 05802510

Country of ref document: EP

Kind code of ref document: A2